SNS-314
CAS No. 1146618-41-8
SNS-314 ( SNS-314 Mesylate | SNS314 | SNS 314 )
产品货号. M10517 CAS No. 1146618-41-8
SNS-314 是一种有效的选择性泛 Aurora 激酶抑制剂,Aurora A 和 Aurora B 的 IC50 分别为 9 和 31 nM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ¥334 | 有现货 |
|
| 5MG | ¥550 | 有现货 |
|
| 10MG | ¥847 | 有现货 |
|
| 25MG | ¥1693 | 有现货 |
|
| 50MG | ¥2465 | 有现货 |
|
| 100MG | ¥3717 | 有现货 |
|
| 500MG | ¥7875 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥635 | 有现货 |
|
生物学信息
-
产品名称SNS-314
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述SNS-314 是一种有效的选择性泛 Aurora 激酶抑制剂,Aurora A 和 Aurora B 的 IC50 分别为 9 和 31 nM。
-
产品描述SNS-314 is a potent, selective pan-Aurora kinase inhibitor with IC50 of 9 and 31 nM for Aurora A and Aurora B, repectively; demonstrates broad activity in vitro against multiple human cancer cell lines and exhibits significant in vivo activity against a wide range of tumor xenograft models; shows additive antiproliferative effects with carboplatin, gemcitabine, 5-FU, daunomycin, and SN-38 both in vitro and in vivo.Solid Tumors Phase 1 Discontinued(In Vitro):SNS-314 blocks proliferation in a broad panel of tumor cell lines (HCT116, A2780, PC-3, HeLa, MDA-MB-231, H-1299, and HT29) with IC50 values ranging from 1.8 nM in A2780 ovarian cancer cells to 24 nM in HT29 colon cancer cells.(In Vivo):In the HCT116 human colon cancer xenograft model, administration of 50 and 100 mg/kg SNS-314 leads to dose-dependent inhibition of histone H3 phosphorylation for at least 10 h. SNS-314 shows significant tumor growth inhibition in a dose dependent manner under a variety of dosing schedules including weekly, bi-weekly, and 5 days on/9 days off.
-
体外实验SNS-314 blocks proliferation in a broad panel of tumor cell lines (HCT116, A2780, PC-3, HeLa, MDA-MB-231, H-1299, and HT29) with IC50 values ranging from 1.8 nM in A2780 ovarian cancer cells to 24 nM in HT29 colon cancer cells.
-
体内实验In the HCT116 human colon cancer xenograft model, administration of 50 and 100 mg/kg SNS-314 leads to dose-dependent inhibition of histone H3 phosphorylation for at least 10 h. SNS-314 shows significant tumor growth inhibition in a dose dependent manner under a variety of dosing schedules including weekly, bi-weekly, and 5 days on/9 days off.
-
同义词SNS-314 Mesylate | SNS314 | SNS 314
-
通路Cell Cycle/DNA Damage
-
靶点Aurora Kinase
-
受体AuroraA|AuroraB|AuroraC
-
研究领域Cancer
-
适应症Solid Tumors
化学信息
-
CAS Number1146618-41-8
-
分子量527.04
-
分子式C19H19ClN6O4S3
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESCS(=O)(=O)O.C1=CC(=CC(=C1)Cl)NC(=O)NC2=NC=C(S2)CCNC3=NC=NC4=C3SC=C4
-
化学全称Urea, N-(3-chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]-, methanesulfonate (1:1)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Oslob JD, et al. Bioorg Med Chem Lett. 2008 Sep 1;18(17):4880-4.
2. VanderPorten EC, et al. Mol Cancer Ther. 2009 Apr;8(4):930-9.
3. Arbitrario JP, et al. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17.
产品手册
关联产品
-
AS 703569
Cenisertib (AS 703569;R763) 是一种新型强效口服 Aurora 激酶抑制剂,在体外和体内对多种肿瘤细胞均表现出显着的抗增殖活性 (A549 EC50=9 nM)。
-
TAS-119
TAS-119 是一种有效的,选择性的,具有口服活性的 Aurora A 抑制剂,IC50 为 1.0 nM。TAS-119 对 Aurora A 的选择性高于其他蛋白激酶,包括 Aurora B (IC50 为 95 nM)。TAS-119 具有有效的抗肿瘤活性。
-
CCT 137690
一种有效的、口服生物可利用的 Aurora 激酶抑制剂,对于 Aurora A/B/C 的 IC50 为 15/25/19 nM;在一系列人类肿瘤细胞系中表现出抗增殖活性,包括 SW620 结肠癌 (GI50=0.30 uM) 和 A2780 卵巢癌细胞系 (GI50=0.14 uM);在 SW620 结肠癌异种移植物中表现出体内功效,未观察到毒性。
021-51111890
购物车()
sales@molnova.cn

